RNS System - Long-Term Post-Approval Study

About NeuroPace

NeuroPace's mission is to transform the lives of people suffering from drug-resistant epilepsy through its innovative, data-driven neuromodulation platform. Its core achievement is the 2013 FDA approval and subsequent commercialization of the RNS System, a first-in-class responsive neurostimulator that has treated thousands of patients. The company's strategy is to deepen its penetration in the focal epilepsy market, expand into new neurological indications, and leverage its proprietary brain data platform to establish a new standard of care in personalized neuromodulation.

Therapeutic Areas

Other Drug-Resistant Focal Epilepsy Drugs